SARS-CoV-2

Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

02/03/2022

Funding from the Bill & Melinda Gates Foundation will support the development of Aridis’ inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 Excerpt from the Press Release: OS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat…

Read More

Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

02/02/2022

Excerpt from the Press Release: STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells. STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans. SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today…

Read More

Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK

01/31/2022

COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in these randomized, double-blind, placebo-controlled Phase 2 trials in the US and UK. COVI-DROPS™ neutralizing antibody was administered as a single low dose intranasal instillation. Results indicate COVI-DROPS is highly active against the original SARS-CoV-2 virus, as well as the variants of concern including highly transmissible and virulent Delta variant…

Read More

Frontiers in Immunology Publishes New Study Data from IncellDx Supporting a Model for Understanding Long COVID’s Cause

01/24/2022

Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–IncellDx, a precision medicine company, today announced the journal Frontiers in Immunology has published a study detailing a framework for understanding the potential mechanism of, and potential treatment for, Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID. “Recent analysis confirms long…

Read More

Ocugen and Bharat Biotech Say Shot Neutralizes Delta and Omicron

01/21/2022

Excerpt from the Press Release: On Wednesday, partners Ocugen and Bharat Biotech said data from the preliminary analysis of the Covaxin booster shot had been found to neutralize both Omicron and Delta variants of SARS-CoV-2 successfully.  Ocugen Inc., a biopharmaceutical company developing gene therapies to cure blindness diseases and a vaccine to save lives from COVID-19, and partner Bharat Biotech,…

Read More

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

01/20/2022

Excerpt from the Press Release: Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway to Address Omicron and Potential Future SARS-CoV-2 Variants WALTHAM, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company…

Read More

GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19

01/19/2022

– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration – – Submission follows COMET-TAIL Phase 3 data demonstrating that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations – Excerpt from the Press Release: PHILADELPHIA and SAN FRANCISCO, Jan. 13, 2022 (GLOBE…

Read More

Clear Creek Bio Advances Its Highly Potent SARS-CoV-2 PLpro Inhibitors in Discovery of an Oral Direct-Acting Antiviral to Treat COVID-19

01/14/2022

Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery This CRADA was initiated as part of the Antiviral Program for Pandemics (APP) Via APP, Clear Creek will be able to use the NIH’s current and expanded contract resources and NCATS laboratories to prioritize the advancement of antiviral candidates…

Read More

LJI and Charles River Laboratories to collaborate on COVID-19 research

01/12/2022

New agreement paves the way for better mouse models to study how the human immune system fights SARS-CoV-2 Excerpt from the Press Release: LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International, Inc., are launching a new project to uncover exactly how different cells in the human immune system…

Read More

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

01/06/2022

HiFiViral Solution helps to accelerate understanding of the Omicron variant, providing information that is important to public health response Excerpt from the Press Release: MENLO PARK, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate, long-read sequencing technology, today announced that its new HiFiViral SARS-CoV-2 solution has successfully sequenced…

Read More